LBA33 Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial
暂无分享，去创建一个
R. Glasspool | B. Asselain | I. Ray-Coquard | N. Colombo | G. Scambia | P. Scollo | K. Lindemann | F. Heitz | F. Selle | F. Marmé | A. Oaknin | E. Pujade-Lauraine | L. Gladieff | A. Redondo | R. Mądry | C. Dubot | C. Zamagni | C. Blakeley | M. J. Rubio-Pérez | B. Shaw | M. Rubio-Pérez | F. Marme